Can I read Severe and Delayed-onset Acneiform Eruptions as an Adverse Reaction to Regorafenib on EtoBox?

Severe and Delayed-onset Acneiform Eruptions as an Adverse Reaction to Regorafenib by Haruhiko Otsuka; Takeshi Fukumoto; Naomi Kiyota; Chihiro Takemori; Haruki Jimbo; Chikako Nishigori is a Medicine article available to read on EtoBox.

What is Severe and Delayed-onset Acneiform Eruptions as an Adverse Reaction to Regorafenib about?

Regorafenib is an oral multikinase inhibitor targeting several tyrosine kinase receptors including BRAF and epidermal growth factor receptor (EGFR) and is approved as a third-line treatment for metastatic gastrointestinal stromal tumor (GIST). While acneiform eruptions have been observed in patients receiving other BRAF and EGFR inhibitors, the commonly reported adverse reactions to regorafenib are fatigue and palmar-plantar erythrodysesthesia. Herein, we report, to the best of our knowledge, the first case who presented with a severe acneiform eruption 24 months after beginning regorafenib for the treatment of GIST. A 61-year-old woman developed GIST with multiple liver metastases, and she was treated with imatinib and sunitinib. However, these therapies were discontinued, and regorafenib was administered. Twenty-four months after beginning regorafenib, she developed an acneiform eruption on her back. Histopathologic analysis of a skin biopsy from the back revealed neutrophilic suppurative folliculitis. Therefore, she postponed regorafenib administration for 2 months and was treated with topical application of clindamycin phosphate hydrate, which was effective. Consistent with rep

Who reads Severe and Delayed-onset Acneiform Eruptions as an Adverse Reaction to Regorafenib?

Author

Haruhiko Otsuka; Takeshi Fukumoto; Naomi Kiyota; Chihiro Takemori; Haruki Jimbo; Chikako Nishigori

Publisher

PAGEPress Publications

Published

2022

Language

EN

Field

Medicine (Health Sciences)